Natriuretic peptides are more than heart failure biomarkers—they regulate immune, metabolic, and cardiovascular systems
Natriuretic peptides (ANP, BNP, CNP) function as multi-system regulators beyond simple heart stress markers, with therapeutic potential across heart failure, kidney disease, and metabolic conditions when their signaling is enhanced.
Quick Facts
What This Study Found
Natriuretic peptides act as multisystem regulators with natriuretic, vasodilatory, antifibrotic, and immunomodulatory effects via cGMP-PKG signaling, but their therapeutic potential is limited by NP resistance mechanisms including neprilysin degradation, NPR-C clearance, and receptor desensitization in advanced disease.
Key Numbers
Reviews PARADIGM-HF, PARAGON-HF, and EMPEROR-Preserved trial data. Discusses ARNIs, designer peptides, NPR-C modulation, and receptor sensitizers as therapeutic approaches.
How They Did This
Narrative review integrating human physiology, preclinical studies, and major clinical trials (PARADIGM-HF, PARAGON-HF, EMPEROR-Preserved), plus analysis of emerging therapeutic agents.
Why This Research Matters
Understanding natriuretic peptides as therapeutic targets rather than just diagnostic markers could unlock new treatment strategies for heart failure, obesity-related cardiovascular disease, and immune-cardiometabolic syndromes. Overcoming NP resistance is key to realizing this potential.
The Bigger Picture
Natriuretic peptides sit at the intersection of cardiology, immunology, and metabolism—three fields increasingly recognized as interconnected. This review frames peptide-based therapies as a bridge across these disciplines, with implications for personalized medicine approaches based on patient phenotyping.
What This Study Doesn't Tell Us
This is a narrative review, not a systematic review or meta-analysis. Many of the proposed therapeutic strategies remain preclinical or in early-phase trials. The translational roadmap proposed is largely theoretical and requires validation.
Questions This Raises
- ?Can designer natriuretic peptides overcome resistance mechanisms more effectively than current ARNIs?
- ?Which patient phenotypes are most likely to benefit from NP augmentation therapy?
- ?How might combining NP-based therapies with SGLT2 inhibitors improve outcomes in obesity-related HFpEF?
Trust & Context
- Key Stat:
- Beyond biomarkers Natriuretic peptides regulate cardiovascular, renal, metabolic, and immune pathways—but resistance mechanisms limit their therapeutic potential in advanced disease
- Evidence Grade:
- Narrative review synthesizing major clinical trials (PARADIGM-HF demonstrated clear benefit of ARNIs in HFrEF) and preclinical evidence. Well-sourced but not a systematic analysis.
- Study Age:
- Published in 2025; incorporates the latest clinical trial data and emerging therapeutic strategies for NP augmentation.
- Original Title:
- Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.
- Published In:
- Cardiovascular drugs and therapy (2025)
- Authors:
- Panneflek, Jathniel, Barbarawi, Mahmoud, Kakarlapudi, Yasitha, Barbarawi, Zaid, Lauzea, Béatrice, Meraz-Torres, Manolo
- Database ID:
- RPEP-12942
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What are natriuretic peptides and why are they important?
Natriuretic peptides (ANP, BNP, CNP) are hormones released primarily by the heart that regulate blood pressure, fluid balance, and inflammation. They are widely used as blood test biomarkers for heart failure, but this review shows they also actively protect the heart, kidneys, and immune system through cGMP signaling.
What is NP resistance and why does it matter?
NP resistance occurs when the body breaks down natriuretic peptides too quickly (via neprilysin enzyme) or their receptors become desensitized, reducing their protective effects. This is especially problematic in advanced heart failure and obesity, and overcoming it is a major goal of new peptide-based therapies like ARNIs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12942APA
Panneflek, Jathniel; Barbarawi, Mahmoud; Kakarlapudi, Yasitha; Barbarawi, Zaid; Lauzea, Béatrice; Meraz-Torres, Manolo. (2025). Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-025-07821-y
MLA
Panneflek, Jathniel, et al. "Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.." Cardiovascular drugs and therapy, 2025. https://doi.org/10.1007/s10557-025-07821-y
RethinkPeptides
RethinkPeptides Research Database. "Natriuretic Peptides as Multisystem Regulators: From Clinica..." RPEP-12942. Retrieved from https://rethinkpeptides.com/research/panneflek-2025-natriuretic-peptides-as-multisystem
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.